Synthesis of Olaparib derivatives and their antitumor activities

Abstract

A series of Olaparib derivatives was synthesized, and their structures were confirmed by ¹H NMR, MS and elemental analysis. Their antitumor activities on breast cancer susceptbility gene 1/2(BRCA1/2)-deficient cancer cell lines including HCC1937, Capan-1 and MDA-MB-436 were evaluated. The antitumor activity of compound Olaparib-1 was better than the positive control Olaparib in BRCA1-deficient cell line HCC1937.

Keywords

Olaparib derivative / BRCA1/2 / Antitumor activity

References

[1] Beral V. Lancet., 2003, 362: 419.

[2] Colditz G. A. Cancer, 1993, 71: 1480.

[3] Easton D. F., Pooley K. A., Dunning A. M., Pharoah P. D. P., Thompson D., Ballinger D. G., Struewing J. P., Morrison J., Field H. Nature, 2007, 447: 1087.

[4] Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M. Science, 1994, 266: 66.

[5] Szabo C. I., King M. C. Mol. Genet., 1995, 4: 1811.

[6] Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gubs C. Nature, 1995, 378: 789.

[7] Tavtigian S. V., Simard J., Rommens J., Couch F., Shattuck-Eidens D., Neuhausen S., Merajver S., Thorlacius S., Offit K. Nat. Genet., 1996, 12: 333.

[8] Bryant E., Schultz N., Thomas H. D., Parker K. M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N. J. Nature, 2005, 434: 913.

[9] Farmer H., McCabe N., Lord C. J., Tutt A. N. J., Johnson D. A., Richardson T. B., Santarosa M., Dillon K. J., Hickson I. Nature, 2005, 434: 917.

[10] Kummar S., Kinders R. J., Rubinstein L., Parchment R. E., Murgo A. J., Collins J., Pickeral O., Low J., Steinberg S. M., Gutierrez M., Yang S., Helman L., Wiltrout R., Tomaszewski J. E., Doroshow J. H. Nature Reviews: Cancer, 2007, 7: 131.

[11] Thomas H. D., Calabrese C. R., Batey M. A., Canan S., Hostomsky Z., Kyle S., Maegley K. A., Newell D. R., Skalitzky D., Wang L. Z., Webber S. E., Curtin N. J. Mol. Cancer Ther., 2007, 6: 945.

[12] Jones P., Altamura S., Boueres J., Ferrigno F., Fonsi M., Giomini C., Lamartina S., Monteagudo E., Ontoria J. M., Orsale V., Pesci S., Roscilli G., Rowley M., Scarpelli R., Schultz-Fademrecht C., Toniatti C. J. Med. Chem., 2009, 52: 7170.

[13] Wang C., Bedikian A., Kim K., Papadopoulos N., Hwu W., Hwu P. Proc. Am. Soc. Clin. Oncol., 2006, 25: 12015.

[14] Yap T. A., Boss D. A., Fong P. C., Roelvink M., Tutt A. J., Carmicchael J., O’Connor M. J., Kaye S. B., Schellens J. H. J. Clin. Oncol., 2007, 25: 3529.

[15] Menear K. A., Adcock C., Boulter R., Cockcroft X., Copsey L., Cranston A., Dillon K. J., Drzewiecki J., Garman S., Gomez S., Javaid H., Kerrigan F., Knights C., Lau A., Loh V. M. Jr., Matthews I. T. W., Moore S., O’Connor M. J., Smith G. C. M., Martin N. M. B. J. Med. Chem., 2008, 51: 6581.

[16] Evers B., Drost R., Schut E., de Buin M., vander Burg E., Derksen P. W. B., Holstege H., Liu X. L., Van Drunen E., Beverloo H. B. Clin. Cancer Res., 2008, 14: 3916.

[17] Penning T. D., Zhu G. D., Gong J., Thomas S., Gandhi V. B., Liu X., Shi Y., Klinghofer V., Johnson E. F., Park C. H. J. Med. Chem., 2010, 53: 3142.

[18] Zhu G. D., Gong J., Gandhi V. B., Liu X., Shi Y., Johnson E. F., Donawho C. K., Ellis P. A., Bouska J. J., Osterling D. J. Bioorg. Med. Chem., 2012, 20: 4635.

[19] Reiner T., Keliher E. J., Earley S., Marinelli B., Weissleder R. Angew. Chem. Int. Ed., 2011, 50: 1922.

[20] Michieletto I., Fabris F., Lucchi O. D. Tetrahedron: Asymmetry, 2000, 11: 2835.

[21] Xawkat A., Ablajan K., Hiraku S. Chem. Res. Chinese Universities, 2009, 25(2): 161.

[22] Zalkow L. H., Hill R. H. Tetrahedron., 1975, 31: 831.

[23] Kobayashi S., Sato M., Eguchi Y., Ohno M. Tetrahedron Lett., 1992, 33: 1081.

[24] Xu H., Hu X. H., Zou X. M., Zhu Y. Q., Liu B., Hu F. Z. Chem. Res. Chinese Universities, 2012, 28(5): 824.

[25] Ismail M. F., Mustafa O. E. A., Amara S. Egyptian Journal of Chemistry, 1994, 37: 8.

[26] Yao H. W., Cui C., Li Y. Q., Wang L. Z., Li Z. M., Zhao W. G. Chem. J. Chinese Universities, 2012, 33(7): 1481.